---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-014263"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T05:19:20.725715+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcus Q2 rev $26.8M, net loss $66.6M; ARC-8 PDAC data similar to historical chemo benchmarks; cash $1.27B

## Summary
- Cash, cash equivalents and investments $1,271.1M at June 30, 2022, up from $681.3M at Dec 2021, driven by $725M Gilead payment.
- Collaboration revenue $26.8M for Q2 2022 vs $9.5M YoY; net loss $66.6M vs $76.0M YoY.
- ARC-8 interim analysis for quemliclustat in PDAC: data from randomized cohort similar to historical chemo benchmarks; Arcus and Gilead await mature data in 2023.
- Four registrational Phase 3 trials of domvanalimab-based combinations ongoing or planned; ARC-7 topline disclosure expected H2 2022.
- AB521 (HIF-2a inhibitor) Phase 1/1b to start Q3 2022; AB801 (AXL inhibitor) nominated; two new molecules expected in clinic in 2023.

## SEC filing metadata
- accession: 0000950170-22-014263
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000095017022014263/0000950170-22-014263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000095017022014263/rcus-20220803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-014263
- JSON: https://secwatch.observer/filing/0000950170-22-014263.json
- Plain text: https://secwatch.observer/filing/0000950170-22-014263.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.